<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02360501</url>
  </required_header>
  <id_info>
    <org_study_id>DCX in NPC</org_study_id>
    <nct_id>NCT02360501</nct_id>
  </id_info>
  <brief_title>Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma</brief_title>
  <official_title>Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Locally Advanced or Metastatic Nasopharyngeal Carcinoma: a Prospective, Phase 2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The standard treatment strategy for locally advanced (stage IVA) and metastatic (stage IVB)
      nasopharyngeal carcinoma has not been defined yet. Generally induction chemotherapy is given
      to those patients in order to shrink the tumor volume and facilitate the following radiation
      therapy. Thus, in this study, the investigators use the combination of
      Docetaxel+Cisplatin+Xeloda (DCX) to treat locally advanced and metastatic nasopharyngeal
      carcinoma patients, in order to evaluate the efficacy and safety profiles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard treatment strategy for locally advanced (stage IVA) and metastatic (stage IVB)
      nasopharyngeal carcinoma has not been defined yet. Generally induction chemotherapy is given
      to those patients in order to shrink the tumor volume and facilitate the following radiation
      therapy.However, the standard chemotherapy regimen has not been defined yet.Combination of
      cisplatin and fluracil is the commonly used regimen with tolerable toxicity. Recent studies
      have found that docetaxel has good efficacy on nasopharyngeal carcinoma patients, and
      capecitabine can be safely used instead of fluracil. Thus, in this study, we use the
      combination of Docetaxel+Cisplatin+Xeloda (DCX) to treat locally advanced and metastatic
      nasopharyngeal carcinoma patients, in order to evaluate the efficacy and safety profiles.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>every 4 weeks,up to completion of treatment(approximately 6 months)</time_frame>
    <description>overall response rate is the sum of complete response rate and partial response rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete response rate</measure>
    <time_frame>every 4 weeks,up to completion of treatment(approximately 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year progression free survival rate</measure>
    <time_frame>date from diagnosis of NPC to disease progression, or death of any cause, whichever comes first （up to 12 months）.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year overall survival rate</measure>
    <time_frame>date from diagnosis of NPC to death of any cause (up to 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety profiles (including hematologic toxicities and non-hematologic toxicities.)</measure>
    <time_frame>date from diagnosis of NPC to completion of study (about 6 months)</time_frame>
    <description>including hematologic toxicities (eg.the incidence rate of neutropenia,thrombocytopenia, and anemia), and non-hematologic toxicities (eg.edema, diarrhea, hand-foot-syndrome).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Nasopharyngeal Neoplasms</condition>
  <arm_group>
    <arm_group_label>treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>docetaxel 75mg/㎡,d1; cisplatin 25mg/㎡,d1-3; capecitabine 2g/㎡, d1-14. repeated every three weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75mg/㎡,d1</description>
    <arm_group_label>treatment arm</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>25mg/㎡,d1-3</description>
    <arm_group_label>treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>2000mg/㎡,d1-14</description>
    <arm_group_label>treatment arm</arm_group_label>
    <other_name>xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stage IVA and IVB nasopharyngeal carcinoma

          -  at lease one measurable lesion

          -  receive no chemotherapy or radiotherapy before

          -  Eastern CooperativeOncology Group performance status of 0 to 2.

          -  Adequate hematologic function (eg, white blood cell ≥ 3×10e9/l,neutrophils count
             ≥1.5×10e9/L, and platelet count≥ 100×10e9/L),renal function (eg, serum creatinine≤1.5
             mg/dL and creatinine clearance ≥50 mL minute), and hepatic function (e.g, total
             bilirubin≤ 2 times the upper limit of normal and aspartate and alanine transaminase
             levels ≤ 3 times the upper limit of normal)

        Exclusion Criteria:

          -  mismatch the inclusion criteria

          -  previous or concomitant malignancies and any coexisting medical problems that could
             cause poor compliance with the study protocol.

          -  allergy to any of these three drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liang Wang, DOCTOR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2015</study_first_submitted>
  <study_first_submitted_qc>February 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2015</study_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Liang Wang</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>nasopharyngeal carcinoma</keyword>
  <keyword>induction chemotherapy</keyword>
  <keyword>docetaxel</keyword>
  <keyword>xeloda</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

